NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rentokil Initial plc (“Rentokil” or “the Company”) (NYSE: RTO). Investors who purchased Rentokil securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RTO.
Investigation Details
On September 11, 2024, Rentokil disclosed that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company’s largest market. Rentokil also stated that it would cut an undisclosed number of jobs in its U.S. workforce to address cost overruns. On this news, Rentokil’s American depositary receipt (“ADR”) price fell $6.64 per ADR, or 21.04%, to close at $24.95 per ADR on September 11, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Rentokil securities, you can assist this investigation by visiting the firm’s site: bgandg.com/RTO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
